Related Experiment Video

Updated: Mar 30, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K

Role of Neprilysin Inhibitors in Heart Failure

Juan P Salazar Adum1, Rohit Arora

  • 11University of Cuenca, Faculty of Medical Sciences, Medical School, Cuenca, Ecuador; and 2Department of Cardiology, Rosalind Franklin University of Medicine and Science, Chicago Medical School, North Chicago, IL.

American Journal of Therapeutics
|November 19, 2015
PubMed

Insights

Neprilysin inhibitors offer a new approach to treating heart failure (HF) by protecting beneficial natriuretic peptides. Newer therapies like LCZ696 show potential benefits for HF patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) remains a significant global health challenge despite advances in treatment.
  • The complex nature of HF necessitates diverse therapeutic strategies.
  • Current HF management faces limitations in addressing its widespread impact.

Purpose of the Study:

  • To review the role of neprilysin inhibitors in managing heart failure.
  • To analyze the impact of neprilysin inhibition on natriuretic peptide levels.
  • To focus on novel neprilysin inhibitors, specifically LCZ696, and their demonstrated benefits.

Main Methods:

  • Literature review of studies on neprilysin inhibitors in heart failure.
  • Analysis of the mechanism of action of neprilysin in HF pathophysiology.
  • Examination of clinical trial data for LCZ696 and similar agents.

Main Results:

  • Neprilysin inhibition preserves natriuretic peptides, counteracting HF's detrimental effects.
  • LCZ696 has demonstrated significant potential benefits in HF patient populations.
  • This class of drugs represents a paradigm shift in HF treatment titration.

Conclusions:

  • Neprilysin inhibitors are a valuable addition to the therapeutic arsenal for heart failure.
  • Targeting neprilysin offers a promising strategy to improve HF outcomes.
  • Further research and clinical application of agents like LCZ696 are warranted.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K